Outcome assessments according to enoxaparin randomization
| . | Fixed-dose enoxaparin (n = 23) . | Weight-adjusted enoxaparin (n = 24) . |
|---|---|---|
| Median number of days hospitalized (range) | 5 (2-14) | 6 (2-14) |
| Median study day numbers of ultrasounds (range) | 18 (10-44) | Not applicable |
| Hemorrhages, no.of patients | ||
| Major | 0 | 0 |
| Clinically relevant non-major | 1 | 0 |
| VTE: during blinded assessment period | 0 symptomatic VTE | 0 symptomatic VTE |
| 1 incidentally identified filling defect within segmental branch of left pulmonary artery (asymptomatic) | ||
| VTE: end of study | 0 symptomatic VTE | 0 symptomatic VTE |
| 2 distal DVTs on surveillance ultrasound (asymptomatic) |
| . | Fixed-dose enoxaparin (n = 23) . | Weight-adjusted enoxaparin (n = 24) . |
|---|---|---|
| Median number of days hospitalized (range) | 5 (2-14) | 6 (2-14) |
| Median study day numbers of ultrasounds (range) | 18 (10-44) | Not applicable |
| Hemorrhages, no.of patients | ||
| Major | 0 | 0 |
| Clinically relevant non-major | 1 | 0 |
| VTE: during blinded assessment period | 0 symptomatic VTE | 0 symptomatic VTE |
| 1 incidentally identified filling defect within segmental branch of left pulmonary artery (asymptomatic) | ||
| VTE: end of study | 0 symptomatic VTE | 0 symptomatic VTE |
| 2 distal DVTs on surveillance ultrasound (asymptomatic) |